Bayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failure (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - August 28, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumors (Source: Bayer Company News)
Source: Bayer Company News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Bayer receives approval for Xofigo ® in China (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas
Deal value up to USD 98 million including increased equity stake and joint development of digital health platform / Collaboration reinforces Bayer’s commitment to developing integrated care solutions for patients (Source: Bayer Company News)
Source: Bayer Company News - August 24, 2020 Category: Pharmaceuticals Source Type: news

Science Based Targets initiative endorses climate protection targets of Bayer AG
Important step in Bayer becoming climate-neutral by 2030 / Targets integral to Board of Management remuneration (Source: Bayer Company News)
Source: Bayer Company News - August 21, 2020 Category: Pharmaceuticals Source Type: news

Bayer announces resolution of U.S. Essure ™ claims
(Source: Bayer Company News)
Source: Bayer Company News - August 20, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farming
Initial efforts will focus on innovating vegetable varieties that deliver optimized quality and sensory experience / Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore / John Purcell appointed as CEO (Source: Bayer Company News)
Source: Bayer Company News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd. (for specialized target groups only)
Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer’s position in Women’s Healthcare / Upfront consideration of USD 425 million and additional potential consideration in the form of milestone payments (Source: Bayer Company News)
Source: Bayer Company News - August 11, 2020 Category: Pharmaceuticals Source Type: news

Bayer: Solid performance despite COVID-19 impact
Ensuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx& portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx& portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations– agreements in major legacy Monsanto litigation / Core earnings per s...
Source: Bayer Company News - August 4, 2020 Category: Pharmaceuticals Source Type: news

Bayer completes the sale of its Animal Health business unit to Elanco
(Source: Bayer Company News)
Source: Bayer Company News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures
Investment addresses today’s challenge to efficiently transport next-generation therapeutics such as cell and gene therapy to the target and unlock their full potential as innovative therapies for patients / Vesigen’s ARMMs technology enables translation of new modalities such as RNAs and gene-editing complexes into novel treatments for multiple diseases (Source: Bayer Company News)
Source: Bayer Company News - July 22, 2020 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to New Drug Application for vericiguat to treat chronic heart failure (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - July 16, 2020 Category: Pharmaceuticals Source Type: news

Bayer ’ s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes (for specialized target groups only)
Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and ty...
Source: Bayer Company News - July 9, 2020 Category: Pharmaceuticals Source Type: news

Bayer issues new senior bonds with a volume of 6 billion euros
Issuance of four tranches with maturities between 4 and 12 years was substantially oversubscribed (Source: Bayer Company News)
Source: Bayer Company News - July 1, 2020 Category: Pharmaceuticals Source Type: news

Bayer announces agreements to resolve major legacy Monsanto litigation
Company will make a total payment of $10.1 billion to $10.9 billion (EUR 9.1 billion to EUR 9.8 billion) to resolve current and address potential future Roundup™ litigation / Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million / Funding sourced from free cash flow and Animal Health divestment / Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs (Source: Bayer Company News)
Source: Bayer Company News - June 24, 2020 Category: Pharmaceuticals Source Type: news